Revisiting the multiple sclerosis functional composite: Proceedings from the National Multiple Sclerosis Society (NMSS) task force on clinical disability measures

Multiple Sclerosis Journal

Volumn 18, Issue 8, 2012, Pages 1074-1080

  Ontaneda, D ^a   Larocca, N ^b   Coetzee, T ^b   Rudick, R A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b National Multiple Sclerosis Society   (United States)

Author keywords

biomarker; clinical trials; multiple sclerosis functional composite; Outcome assessment

Indexed keywords

DRUG INDUSTRY; GOVERNMENT REGULATION; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH PROGRAM; MEDICAL SOCIETY; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; NATIONAL MULTIPLE SCLEROSIS SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; REVIEW; UNITED STATES;

EID: 84864149880     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512451512     Document Type: Review

References (57)

1. Herndon RM. Multiple Sclerosis. Proceedings of the International Conference on Therapeutic Trials in Multiple Sclerosis ; 1983 Grand Island, NY ; 1983. 666.
2. Whitaker JN, McFarland HF, Rudge P, et al. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler. 1995 ; 1: 37-47
3. Rudick R, Antel J, Confavreux C, et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol. 1996 ; 40: 469-479
4. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol. 1997 ; 42: 379-382
5. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999 ; 122 (Pt 5). 871-882
6. Cohen JA, Reingold SC, Polman CH, et al. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol. 2012 ; 11: 467-476
7. Miller DM, Rudick RA, Cutter G, et al. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol. 2000 ; 57: 1319-1324
8. Rudick RA, Polman CH, Cohen JA, et al. Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler. 2009 ; 15: 984-997
9. Costelloe L, O'Rourke K, McGuigan C, et al. The longitudinal relationship between the patient-reported Multiple Sclerosis Impact Scale and the clinician-assessed Multiple Sclerosis Functional Composite. Mult Scler. 2008 ; 14: 255-258
10. Ozakbas S, Cagiran I, Ormeci B, et al. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis. J Neurol Sci. 2004 ; 218: 3-7
11. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002 ; 59: 679-687
12. Miller DM, Rudick RA, Baier M, et al. Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2003 ; 9: 1-5
13. Kaufman M, Moyer D, Norton J. The significant change for the timed 25-foot walk in the multiple sclerosis functional composite. Mult Scler. 2000 ; 6: 286-290
14. Schwid SR, Goodman AD, McDermott MP, et al. Quantitative functional measures in MS: what is a reliable change?. Neurology. 2002 ; 58: 1294-1296
15. Hoogervorst EL, Kalkers NF, Cutter GR, et al. The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult Scler. 2004 ; 10: 55-60
16. Bosma LV, Kragt JJ, Knol DL, et al. Clinical scales in progressive MS: predicting long-term disability. Mult Scler. 2012 ; 18: 345-350
17. Bosma LV, Kragt JJ, Brieva L, et al. Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?. Mult Scler. 2010 ; 16: 862-867
18. Kalkers NF, Bergers L, de Groot V, et al. Concurrent validity of the MS Functional Composite using MRI as a biological disease marker. Neurology. 2001 ; 56: 215-219
19. Fisher E, Rudick RA, Cutter G, et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler. 2000 ; 6: 373-377
20. Cadavid D, Kim S, Peng B, et al. Clinical consequences of MRI activity in treated multiple sclerosis. Mult Scler. 2011 ; 17: 1113-1121
21. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 387-401
22. Balcer LJ, Galetta SL, Calabresi PA, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007 ; 68: 1299-1304
23. Beatty WW, Goretti B, Siracusa G, et al. Changes in neuropsychological test performance over the workday in multiple sclerosis. Clin Neuropsychol. 2003 ; 17: 551-560
24. Bever CT, Grattan L, Panitch HS, et al. The Brief Repeatable Battery of Neuropsychological Tests for Multiple Sclerosis: a preliminary serial study. Mult Scler. 1995 ; 1: 165-169
25. Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol. 2001 ; 58: 961-967
26. Cohen JA, Fischer JS, Bolibrush DM, et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology. 2000 ; 54: 802-806
27. Chronicle EP, MacGregor E. Are PASAT scores related to mathematical ability?. Neuropsychol Rehabil. 1998 ; 8: 273-282
28. Hiscock M, Caroselli JS, Kimball LE. Paced serial addition: modality-specific and arithmetic-specific factors. J Clin Exp Neuropsychol. 1998 ; 20: 463-472
29. Tombaugh TN. A comprehensive review of the Paced Auditory Serial Addition Test (PASAT). Arch Clin Neuropsychol. 2006 ; 21: 53-76
30. Deloire MS, Bonnet MC, Salort E, et al. How to detect cognitive dysfunction at early stages of multiple sclerosis?. Mult Scler. 2006 ; 12: 445-452
31. Strober L, Englert J, Munschauer F, et al. Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS. Mult Scler. 2009 ; 15: 1077-1084
32. Langdon D, Amato M, Boringa J, et al. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler. 2012 ; 18: 891-898
33. Drake AS, Weinstock-Guttman B, Morrow SA, et al. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler. 2010 ; 16: 228-237
34. Brochet B, Deloire MS, Bonnet M, et al. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study. Mult Scler. 2008 ; 14: 1242-1249
35. Holmen C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler. 2011 ; 17: 708-719
36. Amato MP, Portaccio E, Goretti B, et al. Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. Mult Scler. 2010 ; 16: 1474-1482
37. Morrow SA, O'Connor PW, Polman CH, et al. Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler. 2010 ; 16: 1385-1392
38. Benedict RH, Duquin JA, Jurgensen S, et al. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler. 2008 ; 14: 940-946
39. Morrow SA, O'Connor PW, Polman CH, et al. Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler. 2010 ; 16: 1385-1392
40. Benedict RH, Smerbeck A, Parikh R, et al. Reliability and equivalence of alternate forms for the Symbol Digit Modalities Test: implications for multiple sclerosis clinical trials. Mult Scler. :
41. Stankiewicz JM, Glanz BI, Healy BC, et al. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging. 2011 ; 21: e50 - e56
42. Houtchens MK, Benedict RH, Killiany R, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology. 2007 ; 69: 1213-1223
43. Bomboi G, Ikonomidou VN, Pellegrini S, et al. Quality and quantity of diffuse and focal white matter disease and cognitive disability of patients with multiple sclerosis. J Neuroimaging. 2011 ; 21: e57 - e63
44. Langdon D, Amato M, Boringa J, et al. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler. 2012 ; 18: 891-898
45. Bruce JM, Bruce AS, Arnett PA. Mild visual acuity disturbances are associated with performance on tests of complex visual attention in MS. J Int Neuropsychol Soc. 2007 ; 13: 544-548
46. Arnett PA, Smith MM, Barwick FH, et al. Oralmotor slowing in multiple sclerosis: relationship to neuropsychological tasks requiring an oral response. J Int Neuropsychol Soc. 2008 ; 14: 454-462
47. Polman CH, Rudick RA. The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology. 2010 ; 74 (Suppl 3). S8 - S15
48. Balcer LJ, Frohman EM. Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity. Neurology. 2010 ; 74 (Suppl 3). S16 - S23
49. Balcer LJ, Baier ML, Cohen JA, et al. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology. 2003 ; 61: 1367-1373
50. Baier ML, Cutter GR, Rudick RA, et al. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology. 2005 ; 64: 992-995
51. Wu GF, Schwartz ED, Lei T, et al. Relation of vision to global and regional brain MRI in multiple sclerosis. Neurology. 2007 ; 69: 2128-2135
52. Mowry EM, Loguidice MJ, Daniels AB, et al. Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry. 2009 ; 80: 767-772
53. Balcer LJ, Galetta SL, Calabresi PA, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007 ; 68: 1299-1304
54. Pineles SL, Birch EE, Talman LS, et al. One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis. Am J Ophthalmol. 2011 ; 152: 133-140
55. Fox RJ, Lee JC, Rudick RA. Optimal reference population for the multiple sclerosis functional composite. Mult Scler. 2007 ; 13: 909-914
56. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med. 2008 ; 59: 1-12
57. U.S. Food and Drug Administration.Drug Development Tools (DDT) Qualification Program [online], http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/default.htm (2012, accessed 14 February 2012).